238 related articles for article (PubMed ID: 33202944)
1. Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma.
Fattore L; Mancini R; Ciliberto G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202944
[TBL] [Abstract][Full Text] [Related]
2. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
3. Metabolic rewiring in melanoma drug-resistant cells.
Bristot IJ; Kehl Dias C; Chapola H; Parsons RB; Klamt F
Crit Rev Oncol Hematol; 2020 Sep; 153():102995. PubMed ID: 32569852
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications.
Marzagalli M; Raimondi M; Fontana F; Montagnani Marelli M; Moretti RM; Limonta P
Semin Cancer Biol; 2019 Dec; 59():221-235. PubMed ID: 31265892
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell as therapeutic target for melanoma treatment.
Alamodi AA; Eshaq AM; Hassan SY; Al Hmada Y; El Jamal SM; Fothan AM; Arain OM; Hassan SL; Haikel Y; Megahed M; Hassan M
Histol Histopathol; 2016 Dec; 31(12):1291-301. PubMed ID: 27301538
[TBL] [Abstract][Full Text] [Related]
7. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
Hammerlindl H; Schaider H
J Cell Commun Signal; 2018 Mar; 12(1):133-141. PubMed ID: 29192388
[TBL] [Abstract][Full Text] [Related]
8. The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells.
Marcucci F; Ghezzi P; Rumio C
Mol Cancer; 2017 Jan; 16(1):3. PubMed ID: 28137290
[TBL] [Abstract][Full Text] [Related]
9. Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells.
Yang C; Tian G; Dajac M; Doty A; Wang S; Lee JH; Rahman M; Huang J; Reynolds BA; Sarkisian MR; Mitchell D; Deleyrolle LP
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267434
[TBL] [Abstract][Full Text] [Related]
10. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
[TBL] [Abstract][Full Text] [Related]
11. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
Kumar D; Gorain M; Kundu G; Kundu GC
Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.
Cierlitza M; Chauvistré H; Bogeski I; Zhang X; Hauschild A; Herlyn M; Schadendorf D; Vogt T; Roesch A
Exp Dermatol; 2015 Feb; 24(2):155-7. PubMed ID: 25453510
[TBL] [Abstract][Full Text] [Related]
14. Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics.
Poli V; Fagnocchi L; Zippo A
Stem Cells Int; 2018; 2018():4598195. PubMed ID: 29853913
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of Melanoma with Stem Cell Properties.
Seftor EA; Margaryan NV; Seftor REB; Hendrix MJC
Adv Exp Med Biol; 2019; 1139():105-114. PubMed ID: 31134497
[TBL] [Abstract][Full Text] [Related]
16. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance.
Moore N; Lyle S
J Oncol; 2011; 2011():. PubMed ID: 20936110
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming of central carbon metabolism in cancer stem cells.
Wong TL; Che N; Ma S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1728-1738. PubMed ID: 28502706
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating
Yu Y; Wang X; Li Q; Zhang M; Xu P; Chen Y; Yan Y; Zhang L
Oncol Lett; 2018 Jan; 15(1):635-641. PubMed ID: 29387237
[TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell Metabolism and Potential Therapeutic Targets.
Snyder V; Reed-Newman TC; Arnold L; Thomas SM; Anant S
Front Oncol; 2018; 8():203. PubMed ID: 29922594
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.
De Francesco EM; Sotgia F; Lisanti MP
Biochem J; 2018 May; 475(9):1611-1634. PubMed ID: 29743249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
